Single-cell RNA sequencing is a powerful tool for studying cellular diversity, for example in cancer where varied tumor cell types determine diagnosis, prognosis and response to therapy. Single-cell technologies generate ...
Dec 3, 2018
0
0
Researchers at the Johns Hopkins Kimmel Cancer Center say they have added to evidence that measuring and monitoring tumor DNA that naturally circulates in the blood of melanoma patients can not only reliably help reveal the ...
Nov 26, 2018
0
14
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...
Oct 15, 2018
0
77
In a recent study published in Science Advances, Charles E. Gast and co-workers detail the spontaneous process of cancer cell fusion with white blood cells to produce heterogenous hybrid clones in multiple biological systems, ...
What if social behavior affected the progression of even noncontagious diseases? This has now been demonstrated by French CNRS teams and international collaborators. Using a fly model of intestinal cancer, the researchers ...
Sep 4, 2018
0
2
An evolutionary model utilizing serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies in a phase II trial could predict personalized waiting time for progression.
Aug 30, 2018
0
1
Tumor heterogeneity describes the differences between different cells within a given tumor. These differences have major implications for the diagnosis, prognosis, and therapy of cancer patients. Different mechanisms have ...
Apr 19, 2018
0
0
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology ...
Apr 12, 2018
0
3
About half of all melanomas have mutations in the BRAF gene that accelerate tumor cell growth and spread. While most patients benefit from targeted anti-BRAF therapy, resistance to treatment and tumor progression is almost ...
Apr 12, 2018
0
2
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...
Jan 15, 2018
1
404
